Oramed Pharmaceuticals (ORMP)
(Delayed Data from NSDQ)
$2.34 USD
0.00 (0.00%)
Updated May 2, 2024 04:00 PM ET
After-Market: $2.34 0.00 (0.00%) 6:38 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Oramed Pharmaceuticals Inc. [ORMP]
Reports for Purchase
Showing records 61 - 80 ( 80 total )
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Looking Towards Next Round of Catalysts; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Phase 2b Primary Endpoint Met; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Phase 2b Primary Endpoint Met; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Unearthing Gems in the Promised Land: An Overview of the Israeli Life Sciences Sector
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Phase 2b Data Release Next Week; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Phase 2b Data Release Next Week; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Approaching a Key Phase 2b Milestone; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Approaching a Key Phase 2b Milestone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
2016 Shaping Up as A Landmark Year; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
2016 Shaping Up as A Landmark Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
China Licensing Deal Finalized; Reiterate Buy and Raising Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
China Licensing Deal Finalized; Reiterate Buy and Raising Price Target
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Approaching China Licensing Deal Finish Line
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Approaching China Licensing Deal Finish Line
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Initiating Coverage with Buy and $24.00 Price Target
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Optimizing Oral Insulin Delivery; Initiating Coverage with Buy and $24.00 Price Target
Provider: H.C. Wainwright & Co., Inc.